Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice

Area of Science:

• Neuroscience
• Regenerative Medicine
• Immunology

Background:

• Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease causing progressive neurological damage.
• Neural stem cells (NSCs) show therapeutic potential in acute models of MS, primarily through immune regulation.
• The chronic relapsing experimental autoimmune encephalomyelitis (CREAE) model closely mimics relapsing-remitting MS.

Purpose of the Study:

• To evaluate intraventricularly injected NSCs in the CREAE mouse model.
• To assess if priming NSCs to oligodendrocyte precursor cells (OPCs) enhances functional recovery and remyelination.
• To investigate the therapeutic efficacy of NSCs and Olig2-primed NSCs in established chronic relapsing disease.

Main Methods:

• Intraventricular injection of NSCs and Olig2-overexpressing NSCs (Olig2-NSCs) into CREAE mice.
• In vivo bioluminescence and biofluorescence imaging to track cell migration to spinal cord lesions.
• Assessment of NSC differentiation, survival, and clinical outcomes in treated mice.

Main Results:

• Both NSCs and Olig2-NSCs migrated to active lesions in the spinal cord.
• Olig2-NSCs predominantly differentiated into OPCs, with significantly higher survival rates than undifferentiated NSCs.
• Both cell types reduced clinical signs of acute and relapsing disease; Olig2-NSCs abrogated relapses when administered early.

Conclusions:

• NSCs and particularly Olig2-NSC-derived OPCs ameliorate established chronic relapsing EAE in mice.
• This study provides the first evidence for the efficacy of NSC-based therapy in a chronic relapsing demyelinating disease model.
• Findings suggest potential for NSC therapy in preventing progressive disease in relapsing-remitting MS patients.